About Bio2 Technologies
Bio2 Technologies is a privately held medical device company headquartered in Woburn, Massachusetts. Our mission is to commercialize a range of products for orthopedic surgery utilizing CLM•BG, our proprietary resorbable biomaterial.
Paul K. Nichols, Jr. | President and CEO
Paul has 38 years experience with rapidly growing companies in the medical device industry, with the past 30 as an executive and entrepreneur in the musculoskeletal sector. Between 1995 and 2005 he was a founder and CEO of three orthopedic surgery technology companies with successful exits, the most recent being Nexa Orthopedics which was acquired by Tornier (NASD:TRNX) in 2007.
Janet Krevolin, Ph.D. | Chief Technical Officer
Janet has over 20 years experience in research and product development in the orthopedic surgery industry. Prior to joining Bio2 she held the position of Vice President, Global Product Development for Zimmer Holdings, Inc. (NYSE:ZMH). Prior responsibilities included management of Zimmer’s European research activities. Janet has a doctorate in Mechanical Engineering from the University of Texas and a bachelors degree from Wellesley College.
Art O’Dea | VP Legal and Regulatory Affairs
Art is responsible for managing Bio2’s legal and regulatory affairs. Art served as VP of Intellectual Property for GEO2 Technologies, where he built the patent portfolio relating to the CLM technology. Prior to GEO2, Art was Patent Counsel for Cognex Corporation where he managed IP matters, including patent prosecution, patent litigation, and IP licensing. Art has a BSME from the University of Vermont, an MS-CIM from BYU, and a JD from the Massachusetts School of Law. He is a member of the Massachusetts Bar and a registered Patent Attorney with the United States Patent and Trademark Office.
Board of Directors
Paul K. Nichols, Jr., Chairman
Cheryl R. Blanchard, Ph.D.
Dr. Blanchard is the CEO of MicroCHIPS. Previously, she was Senior Vice President and Chief Scientific Officer of Zimmer Holdings, Inc. Dr. Blanchard was also General Manager of the Zimmer Biologics business, a venture business within Zimmer that she built through a combination of internal R&D efforts and technology licensing/acquisition activities. Prior to joining Zimmer in October of 2000, Dr. Blanchard served in leadership roles at the Southwest Research Institute, the University of Texas Health Science Center and the Oak Ridge National Laboratory. Dr. Blanchard also served as a Director of ISTO Technologies, Inc and was the founding board chair of OrthoWorx.
Donald W. Grimm
Mr. Grimm retired from Eli Lilly & Company, a research-based pharmaceutical company, in December 1993 after 23 years of service in various executive positions at Lilly. Following these assignments, Mr. Grimm was President and CEO of Hybritech, Inc., a wholly owned subsidiary of Lilly. Mr. Grimm has been a director of Hamilton BioVentures, LLC, a $100 million fund focused primarily on life sciences, since August 2001. In addition, he is currently a director of several private life science companies and has served on the board of Life Technologies for approximately 12 years.
Gary E. Jacobs
Mr. Jacobs is the Managing Director of Jacobs Investment Company, which participates in real estate development and other investment activities throughout the United States and abroad. In addition, he has multi-million dollar investments in several other venture capital funds. Mr. Jacobs’s philanthropic work includes being a past president of the United Jewish Federation of San Diego County. Additionally, Mr. Jacobs and his wife created and funded the Gary and Jerri-Ann Jacobs International Teen Leadership Institute which promotes Muslim / Jewish understanding.
Mr. Intrater has been in the investment banking and financial services industry for over 30 years. He is the President & CEO of Long-Term Solutions, a Multi-Family Office he founded in 2005 to assist multi-generational families of significant net worth with financial, investment, philanthropic and administrative oversight. He also oversees LTS Capital Partner I and II which provides private equity investment capital to companies primarily in the clean technology field. His previous experience includes a role as board member and managing director of Sand Hill Advisors and the founder of Sutter Street Capital Management. Mr. Intrater spent 13 years as Senior Vice President of Lehman Brothers in New York and San Francisco.
Douglas W. Kohrs
Mr. Kohrs has over 30 years of experience in the medical device industry. He was most recently President and CEO of Tornier N.V. a publicly traded orthopedics company and was previously President and Chief Executive Officer of American Medical Systems Holdings, Inc., a publicly held medical device company. Prior to joining AMS, Mr. Kohrs was General Manager of Sulzer Spine-Tech Inc., an orthopedic implant manufacturer of which he was a founding member beginning. During the past 10 years, Mr. Kohrs has served on the board of directors of nine medical device companies, including ev3 Inc., acquired by Covidien Group S.a.r.l in 2010 and Kyphon, Inc., acquired by Medtronic, Inc. in 2007.
Ms. LaBudde is a founder of Envoi Ventures, a venture capital fund which makes investments in seed and early stage life science and technology/IT companies. Earlier in her career, Ms. LaBudde was Director of Business Development for Bausch & Lomb, Inc. where she was involved in over a dozen successful M&A and licensing transactions representing more than $1.5 billion of aggregate value for the company.
Scientific Advisory Board
Thomas W. Bauer M.D., Ph.D.
Dr. Bauer specializes in orthopaedic and gastrointestinal pathology. He holds joint appointments at the Cleveland Clinic in the Institutes of Orthopaedics and Rheumatology as well as Spine, and his research involves mostly orthopaedic biomaterials. He is considered an expert in the mechanisms of success and failure of orthopaedic devices and he has published more than 225 manuscripts and book chapters.
Gabriele Niederauer, Ph.D.
Dr. Niederauer has over 20 years of experience in the study, development, and commercialization of biomaterials for orthopedic, dental, and ENT tissue repair. She is currently the President and CEO of Bluegrass Vascular Technologies, Inc. She previously served as VP of R&D at ENTrigue Surgical (acquired by Arthrocare in 2013) and as Director of R&D at Osteobiologics, Inc.
Charles L. Saltzman, M.D.
Dr. Saltzman is the Chairman of the Department of Orthopaedics at the University Orthopaedic Center of the University of Utah and specializes in surgery of the foot and ankle. He has authored over 130 peer-reviewed publications, 30 book chapters, and co-edited three major textbooks including Surgery of the Foot and Ankle. He is a past president of the American Orthopaedic Foot and Ankle Society.
Richard W. Mott
Mr. Mott is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm. Mr. Mott most recently served as President, CEO and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies that was acquired by Medtronic, Inc. in 2007. Prior to Kyphon, Mr. Mott held several executive positions at Wilson Greatbatch Technologies, Inc., most recently as CEO, as well as executive operating roles within the Bristol-Myers Squibb Company. Mr. Mott is a recipient of the Ernst & Young Entrepreneur of the Year Award and the Frost & Sullivan Technology Leadership of the Year Award.